Seer

Seer is an American biotechnology company, engages in developing nanoparticle technology solutions for researchers in the areas of proteomics information. The company develops Proteograph, an integrated solution comprising consumables, automation instrumentation, and proprietary software that performs proteomics analysis. Seer was incorporated in 2017 and is headquartered in Redwood City, California.
Seer stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Seer balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Seer cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Seer multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Seer profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Seer assets
Seer cash flows

Seer dividend policy

The company doesn't provide dividend

Seer shares

TickerNameTypeNominal valueISINPrice
SEER:USSeerCommon share-US81578P1066$1.9
Seer news
05.05.2022
Seer's GAAP net income for the 3 months of 2022 was $23.646 million, up 43.9% from $16.429 million in the prior year. Revenue increased 53.42 times to $3.312 million from $0.062 million a year earlier.
01.03.2022
Seer's GAAP loss for 2021 was $71.169 million, up 2.2 times from $32.775 million in the previous year. Revenue increased 10.1 times to $6.617 million from $0.656 million a year earlier.
10.11.2021
Seer's GAAP loss for 9M 2021 was $51.43 million, up 2.6 times from $19.839 million in the previous year. Revenue increased 11.1 times to $3.551 million from $0.32 million a year earlier.
13.08.2021
Seer's GAAP loss for 6M 2021 was $33.045 million, up 2.8 times from $11.61 million in the previous year. Revenue increased 5.6 times to $1.396 million from $0.248 million a year earlier.
General information
Company nameSeer
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address3800 Bridge Parkway Suite 102 Redwood City, CA 94065 United States
Mailing address3800 Bridge Parkway Suite 102 Redwood City, CA 94065 United States
Websiteinvestor.seer.bio
Information disclosurewww.sec.gov